Precipio Diagnostics

54 articles about Precipio Diagnostics

• Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® TechnologyPanel-Based Approach of Driver Mutation Detection Proves Crucial for Patient Care

  5/22/2023

  Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression.

• Precipio Shares Growth Catalysts For HemeScreenQ1 Results and catalysts show promising growth trajectory

  5/17/2023

  Specialty cancer diagnostics company Precipio, Inc., will be discussing on ’s shareholders call several growth catalysts that management has been tracking.

• Precipio Announces Q1-2023 Shareholder Update Call

  5/15/2023

  Specialty cancer diagnostics company Precipio, Inc., will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET.

• Precipio Signs Another HemeScreen™ Customer

  5/4/2023

  Specialty cancer diagnostics company Precipio, Inc. announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory.

• Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

  5/4/2023

  Specialty cancer diagnostics company Precipio, Inc. announces another agreement with a new pathology services customer to utilize Precipio’s diagnostic services.

• Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

  4/27/2023

  Specialty cancer diagnostics company Precipio, Inc., announces notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the Company to meet the required minimum $1.00 per share closing bid price of its common stock for 10 consecutive business days for continued inclusion on the Nasdaq Capital Market Exchange.

• Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) CombinedQ1-2023 product revenues approximately $0.76M exceeded the $0.66M combined revenue of Q3+Q4 2022

  4/19/2023

  Specialty cancer diagnostics company Precipio, Inc., announces that Q1-2023 product revenues have surpassed product revenues during the two prior quarters of 2022, and exceed 50% of the entire year of 2022 product revenues of $1.4M.

• Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call

  3/28/2023

  Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday, April 3rd at 5:00 PM ET. The call will include updates on the Company’s current core businesses.

• Precipio Ships First IV-Cell® Order to Major US Healthcare System

  3/21/2023

  Specialty cancer diagnostics company Precipio, Inc. delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics cell culturing media, to a major US healthcare system.

• Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference

  11/7/2022

  Specialty cancer diagnostics company Precipio, Inc. presented at the annual 2022 AMP conference a poster presentation of the results of a groundbreaking study, conducted in collaboration with faculty at the University of Pennsylvania.

• Precipio Announces Third Quarter Shareholder Update Call

  11/2/2022

  Specialty cancer diagnostics company Precipio, Inc., will be hosting its Q3-2022 shareholder update call on Monday, November 14th at 5:00 PM ET.

• Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™Adding customer segment exceeding $100M in market potential

  9/15/2022

  Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a distribution agreement for HemeScreen with a major distribution partner (name withheld as per partner’s policy).

• Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales

  8/24/2022

  Specialty cancer diagnostics company Precipio, Inc., welcomes Sharon Robins as the Company’s Senior Director of Laboratory & Hospital Sales for the Product’s Division.

• Precipio Launches New 1-Step Technology for all HemeScreen Assays

  8/16/2022

  Specialty cancer diagnostics company Precipio, Inc., announces the launch of its second generation of HemeScreen panels.

• Toni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & Development

  8/10/2022

  Specialty cancer diagnostics company Precipio, Inc., welcomes Toni-Ann Mills as the Company’s Senior Director for Learning & Development.

• Precipio to distribute HemeScreen® through Fisher Healthcare channel

  7/20/2022

  Specialty cancer diagnostics company Precipio, Inc., announced that it has entered into an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific to distribute its proprietary HemeScreen assays to its customers.

• Keith Meadors Joins Precipio to Lead its Products Division

  6/13/2022

  Precipio, Inc., announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and market share.

• Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in EuropeThis Regulatory Approval Opens the Company’s Reach to the European Market

  5/24/2022

  Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that it has received CE-IVD approval for sale of its HemeScreen® reagents in the European Union.

• Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference

  4/26/2022

  Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen, its novel diagnostic technology platform, at the Executive War College, organized by publication Dark Daily, the premier laboratory conference.

• Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call

  3/22/2022

  Specialty cancer diagnostics company Precipio, Inc., will be hosting its Q4-2021 and year end shareholder update call on Monday, April 4th at 5:00 PM ET.